1 Recommendations

1.1 Voclosporin with mycophenolate mofetil is recommended, within its marketing authorisation, as an option for treating active class 3 to 5 (including mixed class 3 and 5, and 4 and 5) lupus nephritis in adults. It is only recommended if the company provides voclosporin according to the commercial arrangement.

Why the committee made this recommendation

Treatment options for active lupus nephritis include immunosuppressants such as mycophenolate mofetil. There are several other immunosuppressant options depending on factors such as condition severity, previous treatments and other conditions such as organ damage.

Clinical trial evidence suggests voclosporin with mycophenolate mofetil is more effective at stopping lupus nephritis from getting worse than mycophenolate mofetil alone. Indirect comparisons suggest voclosporin with mycophenolate mofetil is more effective than other immunosuppressant options.

The most likely cost-effectiveness estimates are within what NICE considers an acceptable use of NHS resources. So, voclosporin with mycophenolate mofetil is recommended.